USA flag logo/image

An Official Website of the United States Government

Development of a phage-based technology for eliminating or significantly…

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
77386
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
A062-178-1133
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INTRALYTIX INC
351 W CAMDEN ST STE 100 Baltimore, MD 21201-8603
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2007
Title: Development of a phage-based technology for eliminating or significantly reducing contamination of fruits, vegetables, and red meat with E. coli O157:
Agency / Branch: DOD / ARMY
Contract: W911QY-07-C-0125
Award Amount: $729,993.00
 

Abstract:

The availability of approaches which reduce contamination of foods with bacterial pathogens is of paramount importance for ensuring the safety and operational readiness of US troops worldwide, as well as for the safety of civilian populations. Intralytix, Inc., has developed and is already commercializing a novel antibacterial technology that may become an important method for improving food safety. The technology utilizes bacteriophages, naturally-occurring predators of bacteria, to reduce the levels of their specifically-targeted pathogenic bacteria in a variety of food-processing settings. In response to the US Army's request for applications (and our subsequently receiving a Phase I SBIR award) for the "development of novel, environmentally-friendly, non-chemical approaches for improving the safety of various food products," we (i) developed a phage cocktail (ECP-100) possessing broad-spectrum lytic activity against E. coli 0157:H7, a virulent bacterium responsible for ca. 62,000 foodborne cases of disease/year in the US, and (ii) demonstrated that ECP-100 is effective in reducing contamination of various foods with E. coli 0157:H7. The present Phase II project is critical for supporting additional research required for optimizing ECP-100's production, obtaining regulatory approvals, and subsequent commercialization.

Principal Investigator:

Alexander Sulakvelidze
Chief Scientist
4106252533
asulakvelidze@intralytix.com

Business Contact:

John Vazzana
CEO
4106252415
jvazzana@intralytix.com
Small Business Information at Submission:

INTRALYTIX, INC.
The Columbus Center 701 E. Pratt Street Baltimore, MD 21202

EIN/Tax ID: 522112466
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No